Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
NCT07804186Phase 3Recruiting
- Lead sponsor
- IDEAYA Biosciences (Industry)
- Enrollment
- 450 (estimated)
- Start date
- 1 Sep 2026
- Primary completion
- Mar 2034 (estimated)
- Study completion
- 1 Apr 2034
- Last update posted
- 15 Sep 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- Darovasertib Drug
- Crizotinib (Xalkori) Drug
Conditions and primary outcome
- Uveal Melanoma
Primary outcome
Median relapse-free survival (Approximately 5 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07804186.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07804186 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.